Log in
Enquire now
‌

US Patent 11617749 Ophthalmic formulations of cetirizine and methods of use

Patent 11617749 was granted and assigned to NicOx on April, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
‌
NicOx
0
Current Assignee
‌
NicOx
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
116177490
Patent Inventor Names
Mark Barry Abelson0
Jackie Nice0
George Minno0
Matthew J. Chapin0
Paul Gomes0
Date of Patent
April 4, 2023
0
Patent Application Number
170188650
Date Filed
September 11, 2020
0
Patent Citations
‌
US Patent 10675279 Ophthalmic formulations of cetirizine and methods of use
0
Patent Primary Examiner
‌
Ali Soroush
0
CPC Code
‌
A61K 47/26
0
‌
A61K 47/38
0
‌
A61P 37/08
0
‌
A61P 11/02
0
‌
A61P 27/02
0
‌
A61P 27/14
0
‌
A61K 47/02
0
‌
A61K 9/08
0
...

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11617749 Ophthalmic formulations of cetirizine and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.